Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry

Thu Giang Le Thi,Katharina Werkstetter,Kallirroi Kotilea,Patrick Bontems,José Cabral,Maria Luz Cilleruelo,Michal Kori,Josefa Barrio,Matjaž Homan,Nicolas Kalach,Rosa Lima,Marta Tavares,Pedro Urruzuno,Zrinjka Misak,Vaidotas Urbonas,Sibylle Koletzko,for the Helicobacter pylori Special Interest Group of ESPGHAN

DOI: https://doi.org/10.1111/hel.13134

2024-09-10

Helicobacter

Abstract:Background European and North‐American guidelines on management of H. pylori infection in children provide the option not to treat even if the infection is endoscopically confirmed. We used data from the EuroPedHp Registry to identify factors associated with therapy decisions. Methods We included treatment‐naïve patients reported between 2017 and 2020 from 30 centers in 17 European countries. Multivariable logistic regression identified factors including comorbidities within and outside the gastrointestinal (GI) tract influencing the decision for or against therapy. Results Of 1165 patients (52% females, median age 12.8), 28% (321/1165) reported any alarm symptom, 26% (307/1165) comorbidities, and 16% (192/1165) did not receive eradication treatment. Therapy was initiated less often in children having any GI comorbidity (57%, n = 181), particularly in those with eosinophilic esophagitis (60%, n = 35), inflammatory bowel disease (54%, n = 28), and celiac disease (43%, n = 58), compared to those with non‐GI (86%, n = 126) or no comorbidity (89%, n = 858), despite similar frequencies of alarm and non‐alarm symptoms, ulcers, erosions, and nodular gastritis. Patients with GI and without comorbidities remained more likely untreated in high versus low H. pylori prevalence countries (p

gastroenterology & hepatology,microbiology